Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
Open Access
- 4 May 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (10) , 4697-4710
Abstract
Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner. Compounds were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer. Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure–activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target. This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions. Kinase profiling and further optimization resulted in eCF506, the first small molecule with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concentration to inhibit ABL. eCF506 exhibits excellent water solubility, an optimal DMPK profile and oral bioavailability, halts SRC-associated neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.Keywords
Funding Information
- Medical Research Council
- European Research Council (294440)
- Research Councils UK
- Wellcome (WT84637)
- Edinburgh BioQuarter
This publication has 67 references indexed in Scilit:
- Biophysical Methods in Drug Discovery from Small Molecule to Pharmaceutical2013
- Discovery of small molecule cancer drugs: Successes, challenges and opportunitiesMolecular Oncology, 2012
- Advancing Cancer Drug Discovery Towards More Agile Development of Targeted Combination TherapiesFuture Medicinal Chemistry, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- Assessing drug-likeness – what are we missing?Drug Discovery Today, 2008
- Virtual screening strategies in drug discoveryCurrent Opinion in Chemical Biology, 2007
- Why is cancer drug discovery so difficult?Nature Reviews Drug Discovery, 2006
- Screening for drug discovery: The leading questionNature, 2002